Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

70 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Diagnostic markers for early detection of ovarian cancer.
Visintin I, Feng Z, Longton G, Ward DC, Alvero AB, Lai Y, Tenthorey J, Leiser A, Flores-Saaib R, Yu H, Azori M, Rutherford T, Schwartz PE, Mor G. Visintin I, et al. Among authors: leiser a. Clin Cancer Res. 2008 Feb 15;14(4):1065-72. doi: 10.1158/1078-0432.CCR-07-1569. Epub 2008 Feb 7. Clin Cancer Res. 2008. PMID: 18258665
Anti-tumor activity of phenoxodiol: from bench to clinic.
Alvero AB, Kelly M, Rossi P, Leiser A, Brown D, Rutherford T, Mor G. Alvero AB, et al. Among authors: leiser a. Future Oncol. 2008 Aug;4(4):475-82. doi: 10.2217/14796694.4.4.475. Future Oncol. 2008. PMID: 18684059 Review.
Phase I trial of daily subcutaneous SPL-108 injections in combination with paclitaxel in patients with platinum resistant CD44+ advanced ovarian epithelial cancer.
Girda E, Hou J, Nelson D, Finlayson M, de Meritens AB, Chekmareiva M, Leiser A, Song M, Stephenson R, Chan N, Tergas AI, Vattakalam R, Wright JD, Yu H, Martincuks A, Kohut A, Palmer J, Rodriguez-Rodriguez L. Girda E, et al. Among authors: leiser a. Int J Gynecol Cancer. 2022 Jun 24;32(8):1032-8. doi: 10.1136/ijgc-2021-003316. Online ahead of print. Int J Gynecol Cancer. 2022. PMID: 35750354 Free PMC article.
Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers.
Palmeri M, Mehnert J, Silk AW, Jabbour SK, Ganesan S, Popli P, Riedlinger G, Stephenson R, de Meritens AB, Leiser A, Mayer T, Chan N, Spencer K, Girda E, Malhotra J, Chan T, Subbiah V, Groisberg R. Palmeri M, et al. Among authors: leiser a. ESMO Open. 2022 Feb;7(1):100336. doi: 10.1016/j.esmoop.2021.100336. Epub 2021 Dec 23. ESMO Open. 2022. PMID: 34953399 Free PMC article.
Use of comprehensive genomic profiling to direct point-of-care management of patients with gynecologic cancers.
Rodriguez-Rodriguez L, Hirshfield KM, Rojas V, DiPaola RS, Gibbon D, Hellmann M, Isani S, Leiser A, Riedlinger GM, Wagreich A, Ali SM, Elvin JA, Miller VA, Ganesan S. Rodriguez-Rodriguez L, et al. Among authors: leiser a. Gynecol Oncol. 2016 Apr;141(1):2-9. doi: 10.1016/j.ygyno.2016.02.021. Gynecol Oncol. 2016. PMID: 27016222 Free PMC article. Clinical Trial.
70 results